Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tonix Pharmaceuticals Holding (TNXP) Short term Debt: 2023-2024

Historic Short term Debt for Tonix Pharmaceuticals Holding (TNXP) over the last 1 years, with Dec 2024 value amounting to $2.8 million.

  • Tonix Pharmaceuticals Holding's Short term Debt rose 20.00% to $2.8 million in Q4 2024 from the same period last year, while for Dec 2024 it was $2.8 million, marking a year-over-year increase of 20.00%. This contributed to the annual value of $2.8 million for FY2024, which is 20.00% up from last year.
  • According to the latest figures from Q4 2024, Tonix Pharmaceuticals Holding's Short term Debt is $2.8 million, which was down 0.00% from $2.8 million recorded in Q3 2024.
  • Tonix Pharmaceuticals Holding's 5-year Short term Debt high stood at $2.8 million for Q1 2024, and its period low was $2.4 million during Q4 2023.
  • Moreover, its 2-year median value for Short term Debt was $2.8 million (2024), whereas its average is $2.7 million.
  • Data for Tonix Pharmaceuticals Holding's Short term Debt shows a peak YoY grew of 20.00% (in 2024) over the last 5 years.
  • Tonix Pharmaceuticals Holding's Short term Debt (Quarterly) stood at $2.4 million in 2023, then grew by 20.00% to $2.8 million in 2024.
  • Its Short term Debt was $2.8 million in Q4 2024, compared to $2.8 million in Q3 2024 and $2.8 million in Q2 2024.